Irish biotechnology company EiRx Therapeutics has secured a new investment of £3m from European venture capital company 3i, Enterprise Ireland, and AIM-listed fund World Life Sciences.
EiRx, founded last year, says the new funding will enable it to double its staff numbers to around 20.
The company is carrying out research and development in the area of genomics, focusing on a biological process known as apoptosis or cell death.
The objective is to find new drugs to treat conditions such as cancer and Alzheimer's.
